Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study)

OBJECTIVES: Guidelines for treatment of mRCC recommend nivolumab monotherapy (NIVO) for treated patients, and nivolumab plus ipilimumab combination therapy (NIVO+IPI) for untreated IMDC intermediate and poor-risk mRCC patients. Although molecular-targeted therapies (TTs) such as VEGFR-TKIs and mTORi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yoshihiko, Kimura, Go, Fukasawa, Satoshi, Numakura, Kazuyuki, Sugiyama, Yutaka, Yamana, Kazutoshi, Naito, Sei, Kabu, Koki, Tajima, Yohei, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163064/
https://www.ncbi.nlm.nih.gov/pubmed/33594427
http://dx.doi.org/10.1093/jjco/hyaa266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163064/
https://www.ncbi.nlm.nih.gov/pubmed/33594427
http://dx.doi.org/10.1093/jjco/hyaa266

Ejemplares similares